Abstract:BACKGROUND: Fungal infections are the most frequent dermatoses. The gold standard treatment for dermatophytosis is the squalene epoxidase (SQLE) inhibitor terbinafine. Pathogenic dermatophytes resistant to terbinafine are an emerging global threat. Here, we determine the proportion of resistant fungal skin infections, analyse the molecular mechanisms of terbinafine resistance, and validate a method for its reliable rapid identification.METHODS: Between 2013 and 2021, we screened 5634 consecutively isolated Trichophyton for antifungal resistance determined by hyphal growth on Sabouraud dextrose agar medium containing 0.2 μg/mL terbinafine. All Trichophyton isolates with preserved growth capacity in the presence of terbinafine underwent SQLE sequencing. Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method.RESULTS: Over an 8-year period, the proportion of fungal skin infections resistant to terbinafine increased from 0.63% in 2013 to 1.3% in 2021. Our routine phenotypic in vitro screening analysis identified 0.83% (n = 47/5634) of Trichophyton strains with in vitro terbinafine resistance. Molecular screening detected a mutation in the SQLE in all cases. Mutations L393F, L393S, F397L, F397I, F397V, Q408K, F415I, F415S, F415V, H440Y, or A398 A399 G400 deletion were detected in Trichophyton rubrum. Mutations L393F and F397L were the most frequent. In contrast, all mutations detected in T. mentagrophytes/T. interdigitale complex strains were F397L, except for one strain with L393S. All 47 strains featured significantly higher MICs than terbinafine-sensitive controls. The mutation-related range of MICs varied between 0.004 and 16.0 μg/mL, with MIC as low as 0.015 μg/mL conferring clinical resistance to standard terbinafine dosing.CONCLUSIONS: Based on our data, we propose MIC of 0.015 μg/mL as a minimum breakpoint for predicting clinically relevant terbinafine treatment failure to standard oral dosing for dermatophyte infections. We further propose growth on Sabouraud dextrose agar medium containing 0.2 μg/mL terbinafine and SQLE sequencing as fungal sporulation-independent methods for rapid and reliable detection of terbinafine resistance.

Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain

In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis

In Vitro Activities of a Wide Panel of Antifungal Drugs against Various Scopulariopsis and Microascus Species

In Vitro Activities of Terbinafine against Cutaneous Isolates of Candida albicans and Other Pathogenic Yeasts

In vitro susceptibility testing of domestic terbinafine hydrochloride against dermatophytes

Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates

Activities of Terbinafine in Combination with Itraconazole and Fluconazole Against Isolates of Candida albicans In Vitro

In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes

Fungicidal versus fungistatic activity of terbinafine and itraconazole: An in vitro comparison

In vitro determination of the combination of ciclopirox and terbinafine in the treatment of dermatophytosis

Reliable and rapid identification of terbinafine resistance in dermatophytic nail and skin infections

Report of terbinafine resistant Trichophyton spp. in Italy: Clinical presentations, molecular identification, antifungal susceptibility testing and mutations in the squalene epoxidase gene

The Emerging Terbinafine-Resistant Trichophyton Epidemic: What Is the Role of Antifungal Susceptibility Testing?

Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial

In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs

In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles

Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes

Antifungal Susceptibility Testing of Clinical Isolates of Candida Albicans to Terbinafine, Miconazole and Nystatin

Pharmacokinetics and pharmacology of terbinafine and itraconazole